Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.61 |
| ▸ | NOS1 | P29475 | 1/20 | 0.56 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4068320 | 0.93 | CHRM2 (0.68) | CHRM2CYP1A2CYP2D6SIGMAR1NOS1 | |
| SCHEMBL7235869 | 0.90 | CYP1A2 (0.69) | CHRM2CYP1A2CYP2D6LTA4H | |
| SCHEMBL6158945 | 0.90 | SIGMAR1 (0.68) | CHRM2SIGMAR1EPHX2 | |
| SCHEMBL6157520 | 0.89 | CHRM2 (0.71) | CHRM2CYP1A2CYP2D6SIGMAR1NOS1 | |
| Hydrochloric Acid SCHEMBL30115033 | 0.88 | CYP1A2 (0.67) | CHRM2CYP1A2CYP2D6LTA4H | |
| SCHEMBL11594897 | 0.88 | CHRM2 (0.93) | CHRM2CYP1A2CYP2D6SCN8ALTA4H | |
| SCHEMBL6160313 | 0.87 | SIGMAR1 (0.68) | CHRM2SIGMAR1 | |
| SCHEMBL6157737 | 0.87 | SIGMAR1 (0.70) | CHRM2SIGMAR1EPHX2 | |
| SCHEMBL6161198 | 0.87 | SIGMAR1 (0.68) | CHRM2SIGMAR1 | |
| SCHEMBL29761159 | 0.86 | CYP1A2 (0.74) | CHRM2CYP1A2CYP2D6LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1415986-B1 | SPIRO ISOBENZOFURANES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS | BANYU PHARMA CO LTD (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-7205417-B2 | Spiro compounds | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| US-20040259890-A1 | Spiro compounds | MSD K.K. (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-0871615-B1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | MERCK & CO INC (US) | 2004-07-14 | — | — | EP | disclosed |
| EP-1415986-A1 | SPIRO COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-6194581-B1 | FOR TREATMENT OF DYSFUNCTION OF THE CENTRAL OR AUTONOMIC NERVOUS SYSTEMS INCLUDING DEMENTIA, COGNITIVE DISORDERS, NEURODEGENERATIVE DISORDERS, EXTRAPYRAMIDAL DISORDERS, CONVULSIVE DISORDERS, CARDIOVASCULAR DISORDERS, PAIN | MERCK & CO., INC. | 2001-02-27 | — | — | US | disclosed |
| US-5852041-A | Substituted pyridines useful as modulators of acethylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0871615-A1 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5736560-A | USEFUL IN THE TREATMENT OF ALZHEIMER'S AND PARKINSONS'S DISEASES | SIBIA NEUROSCIENCES, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| US-5686473-A | TREATING PARKINSON*S DISEASE, ALZHEIMER*S DISEASE, DEMENTIA AND PAIN | SIBIA NEUROSCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5585388-A | Substituted pyridines useful as modulators of acetylcholine receptors | SIBIA NEUROSCIENCES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| WO-1996031475-A2 | SUBSTITUTED PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MODULATORS OF ACETYLCHOLINE RECEPTORS | SIBIA NEUROSCIENCES, INC. (US) | 1996-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259890-A1 | Spiro compounds | OPRD1, PER2, OPRK1 | CHRM2 128/4885CYP1A2 168/4885CYP2D6 407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.